Moderate hemophilia A

Moderate hemophilia A is a bleeding disorder caused by a partial deficiency of coagulation factor VIII (FVIII), with plasma factor VIII activity levels typically ranging between 1% and 5% of normal. It is also known as moderate factor VIII deficiency or moderate classic hemophilia. The condition primarily affects the blood's ability to clot properly, leading to prolonged and sometimes excessive bleeding following injuries, dental procedures, or surgery. Unlike severe hemophilia A, spontaneous bleeding episodes are less frequent in the moderate form, though they can still occur, particularly into joints (hemarthrosis) and muscles. The condition predominantly affects males, as it follows an X-linked recessive inheritance pattern, while females are typically carriers who may occasionally experience mild bleeding symptoms. The musculoskeletal system is significantly impacted over time, as recurrent joint bleeds can lead to chronic joint damage (hemophilic arthropathy), most commonly affecting the knees, ankles, and elbows. Patients may also experience easy bruising, prolonged bleeding from cuts or wounds, excessive bleeding after surgery or trauma, and occasionally hematuria or gastrointestinal bleeding. Diagnosis is confirmed through coagulation studies showing a prolonged activated partial thromboplastin time (aPTT) and reduced FVIII activity levels, along with genetic testing of the F8 gene located on the X chromosome (Xq28). Treatment for moderate hemophilia A centers on replacement therapy with plasma-derived or recombinant factor VIII concentrates, administered on-demand to treat bleeding episodes or prophylactically in some cases to prevent recurrent bleeds and joint damage. Desmopressin (DDAVP) may be effective in some patients with moderate hemophilia A, as it can temporarily raise FVIII levels by stimulating release of endogenous factor VIII from storage sites. More recently, emicizumab, a bispecific monoclonal antibody that mimics the cofactor function of factor VIII, has been approved as a prophylactic option. A significant complication of treatment is the development of inhibitory antibodies (inhibitors) against factor VIII, though this occurs less frequently in moderate hemophilia A than in the severe form. Comprehensive care through specialized hemophilia treatment centers, including physiotherapy and orthopedic management, is recommended to optimize outcomes.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Moderate hemophilia A